Navigation Links
UC and partners awarded $23 million to transform discoveries into real-world health solutions
Date:4/7/2009

CINCINNATIThe University of Cincinnati (UC) and its affiliated health care partners will receive nearly $23 million from the National Institutes of Health (NIH) to bring innovations from the laboratory bench to the bedside and to applications within the community.

The five-year funding, awarded through the NIH's institutional Clinical and Translational Science Awards (CTSA) program, will be used to support programming within UC's Center for Clinical and Translational Science and Training (CCTST). Established in 2005 as a collaborative effort among UC, Cincinnati Children's Hospital Medical Center, University Hospital and the Cincinnati Department of Veterans Affairs Medical Center, the CCTST is a research resource and "academic home" for clinical and translational scientists and programs.

UC is the first CTSA to be funded in 2009.

"Bench to bedside (translational research) is a common phrase in medicine, and turning laboratory findings into diagnostic tools or therapies for patients is the goal of academic medical centers," said David Stern, MD, College of Medicine dean and UC vice president for health affairs. "The CTSA program is a clear recognition by the NIH of the need to speed up the translation of the important work happening at the basic scientific level, and UC's award is indicative of the quality of scientific discovery happening on our campus and in the labs of our close partners."

CTSA fundingexpected to be given to only 60 institutions nationwide by 2012will eventually replace the NIH's General Clinical Research Center (GCRC) program and various other training programs.

UC's NIH-supported GCRC, housed at Cincinnati Children's Hospital Medical Center, with a satellite operation at the Cincinnati Department of Veterans Affairs Medical Center, is led by James Heubi, MD, of Cincinnati Children's and UC's department of pediatrics, and associate dean for clinical and translational research, and is credited
'/>"/>

Contact: Dama Kimmon
dama.kimmon@uc.edu
513-558-4519
University of Cincinnati
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Oxford Journals and the International Society for Computational Biology announce new partnership
2. NTU seals global partnerships on environmental sciences R&D
3. National Lung Cancer Partnership and LUNGevity Foundation announce 2009 grant recipients
4. International public-private partnership offers new paradigm for medicinal chemistry
5. Springer partners with Botanical Society of Korea
6. New publishing partnership for Energy for Sustainable Development
7. Montana State partnership receives $66.9M for carbon sequestration
8. Elsevier partners with the Royal Netherlands Society for Agricultural Sciences
9. NIH funds 16 Science Education Partnership Awards
10. GUMC and Oak Ridge National Labs announce unique research partnership
11. Annual meeting of Big Sky Carbon Sequestration Partnership to be held Oct. 28, 29
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Bhavani Iyer, O.D., a low vision specialist at The ... Medical School, has been awarded a grant to help ... with eyeglasses, medication or surgery. , Even with corrective ... at best. However, there are a variety of low ... to help offset their vision loss. , Iyer is ...
(Date:7/24/2014)... experts gathered at NJIT this week for an all-day ... U.S. Environmental Protection Agency (EPA) to dredge toxic sediment ... , The EPA has called the plan, which proposes ... capping sections of the riverbed, one of the largest ... be dredged and disposed off-site. , "We need to ...
(Date:7/24/2014)... To reduce fire hazard in the United States, wildland ... woody shrubs and suppressed trees (ladder fuels). These ... periods of low fire danger in order to dispose ... hazardous air pollutants, managers often cover all or part ... referred to as agricultural plastic, in order to keep ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... to the growing list of genetic variants that determine ... by Cell Press on December 30 in the ... previously unknown variants associated with height and might provide ... Although environmental variables can impact attained adult height, ...
... large quantities of nitrate-rich fertilizer to realize optimal ... to balance the amount of nitrogen needed for ... leach into ground and surface waters. Increased interest ... to identify genotypes that have a characteristic called ...
... producers have traditionally relied heavily on hand thinning, a ... increasing labor costs and a limited workforce, peach and ... such as string thinners to minimize the need for ... promising results when it was evaluated in four U.S. ...
Cached Biology News:Large-scale analysis identifies new genetic alterations associated with height 2Improving nitrogen use efficiency lessens environmental impact 2Hybrid string blossom thinner tested in peach orchards 2
(Date:7/25/2014)... 2014 According to a new market ... - Global Industry Analysis, Size, Share, Growth, Trends and ... is estimated at USD 161,056.5 million in 2014 and ... from 2014 to 2020, to reach an estimated value ... drugs market is witnessing a significant growth due to ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... 2011 Operational and Financial Results ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Nov. 11, 2010 StemCyte, Inc., one of the ... companies, is proud to announce that the Company has ... U.S. Internal Revenue Service,s Qualifying Therapeutic Discovery Project (QTDP) ... fewer than 250 employees. The Patient Protection ...
... (Nasdaq: ARAY ), a global leader in the ... to present at the Lazard Capital Markets, Healthcare Conference in ... a.m. ET/7:30 a.m. PT. A live webcast of ... page of the Company,s Web site at http://www.accuray.com . ...
Cached Biology Technology:YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 2YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 3YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 4YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 5YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 6YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 7YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 8YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 9YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 10YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 11YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 12YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 13YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 14StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP) 2Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets' Healthcare Conference 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... of X-ray crystallography services for structure-based ... to its pharmaceutical and biotechnology clients. ... drug-like fragments to the active sites ... scientists to develop novel, high-affinity inhibitors. ...
...
... monitoring acetylcholinesterase (AChE) activity. This is a ... min), non-radioactive and easy to use assay ... substrate, acetylcholine. A series of coupled enzyme ... into a change in luminescence. Inhibitors of ...
Biology Products: